Krystal Biotech (KRYS) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Speaker0 Thank you for standing by, and welcome to the Crystal Biotech First Quarter twenty twenty five Earnings Call. At this time, all participants are on a listen only mode. After the speakers' presentations, there will be a question and answer session. As a reminder, today's conference is being recorded. I would now like to hand the conference over to your host, Stephane Paquette, Vice President of Corporate Development. Please begin. ...

Krystal Biotech Announces First Quarter 2025 Financial and Operating Results VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for the treatment of neurotrophic keratitis Upcoming clinical readouts in 2025 - CF, AATD, ocular complications of DEB, and aesthetics Strong balance sheet, ending the quarter with $765.3 million in cash and investments PITTSBURGH, May 6, 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ FORM 10-Q _____________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38210 _____________ ...

VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK (beremagene geperpavec-svdt) for the treatment of wounds in patients with dy ...

Core Insights - Krystal Biotech, Inc. will present multiple programs related to lung, eye, and skin at scientific conferences in May and June 2025 [1] Conference Presentations - The company will participate in the following conferences: - American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting: Invited Oral Presentation [2] - 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: Poster Presentation [2] - Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting: Poster Presentation [2] - Society for Investigative Dermatology (SID) 2025 Annual Meeting: Poster Presentation [3] Company Overview - Krystal Biotech, Inc. is a global biotechnology company focused on genetic medicines for diseases with high unmet medical needs [4] - The company's first commercial product, VYJUVEK®, is the first-ever redosable gene therapy approved by the FDA for dystrophic epidermolysis bullosa [4] - The company is advancing a pipeline of investigational genetic medicines across various fields including respiratory, oncology, dermatology, ophthalmology, and aesthetics [4]

PITTSBURGH, April 17, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, May 6, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcas ...

PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an ext ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.Krystal Biotech (NASDAQ: KRYS ) has been on the Compounding Healthcare “Bio Boom” speculative portfolio since the investing group’s inception due to their ability to develop cutting-edge “redosable” gene therapies. Although I am a big believer in cell an ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

Core Insights - Krystal Biotech (KRYS) shares have increased by 15.8% over the past month, outperforming the industry growth of 4% [1] - The company reported fourth-quarter 2024 results with earnings exceeding estimates, although sales fell short [1] - The stock's surge post-earnings is attributed to strong uptake of Vyjuvek and positive pipeline developments [1] Vyjuvek Performance - Vyjuvek, the first FDA-approved gene therapy for dystrophic epidermolysis bullosa (DEB), was launched in May 2023 [3] - Sales of Vyjuvek reached $290.5 million, a significant increase from $50.7 million in 2023 [4] - As of February 2025, Krystal secured over 510 reimbursement approvals for Vyjuvek in the U.S., with 97% of lives covered under commercial and Medicaid plans [5] Regulatory Approvals - The European Medicines Agency has recommended the approval of Vyjuvek for DEB treatment [6] - A new drug application for Vyjuvek has been filed in Japan, with a decision expected in the second half of 2025 [6] Pipeline Developments - Krystal is advancing a pipeline of genetic medicines across various fields, including respiratory and oncology [7] - KB407 is being evaluated for cystic fibrosis, with interim data expected in mid-2025 [8] - KB408 is showing promising results for alpha-1 antitrypsin deficiency, with further assessments planned [9] Financial Metrics - KRYS shares currently trade at a price/sales ratio of 10.58x forward sales, lower than its historical mean of 22.83x [13] - The Zacks Consensus Estimate for 2025 earnings per share (EPS) has risen to $7.07 from $5.40 over the past month [14] Cash Position - As of December 31, 2024, Krystal holds a cash balance of $749.6 million, positioning the company well for pipeline development [17] Market Position - Krystal Biotech holds a Zacks Rank 2 (Buy), indicating strong market confidence [18]